| ID | 1148 |
| Name of the vaccine | ActHib |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 2 months to 5 years |
| Description of the vaccine | Haemophilus b conjugate vaccine (Tetanus toxoid conjugate) (PRP-T). |
| Name of the manufacturer | Sanofi Pasteur SA |
| Name of the manufacturing country | France |
| Year of manufacture | 1993 |
| Clinical Phase status | Approved |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Lyophilized powder to be reconstituted in supplied 0.4% Sodium Chloride diluent. |
| Dosage | Four dose series (0.5 ml each). Primary series: One dose at 2, 4, and 6 months.
Booster: One dose at 15 through 18 months.
|
| Mechanism of action | T-dependent immune response to antigens.
anti-PRP of greater than 1.0 mcg/mL : Long-term protection |
| Route of administration | Intramuscular |
| Indications | Prevention of invasive disease caused by Haemophilus influenzae type b. |
| Export | Distributed by - Sanofi Pasteur Inc., USA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Children (2 to 16 months) : irritability, inconsolable crying and lethargy.
Children (15-20 months): tenderness |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/74395/download |
| Other name | NA |
| Additional Links | NA
|